Fig. 4: Clinical protection in chickens immunized with NR-3M2e or NF-3M2e supplemented with HA1, or each component alone, after infection with heterologous HPAI H5N1 virus. | npj Vaccines

Fig. 4: Clinical protection in chickens immunized with NR-3M2e or NF-3M2e supplemented with HA1, or each component alone, after infection with heterologous HPAI H5N1 virus.

From: M2e nanovaccines supplemented with recombinant hemagglutinin protect chickens against heterologous HPAI H5N1 challenge

Fig. 4

Chickens received at 2-week intervals three intramuscular administrations of HA1 protein in combination with NF-3M2e or NR-3M2e, or each single component alone. Chickens receiving PBS were included as a control group. All preparations were admixed with Emulsigen®-P. Two weeks after the third immunization, all chickens were challenged with 2.3 × 102 PFU of heterologous HPAI H5N1 virus and monitored daily for mortality. The survival curves of infected chickens are expressed as the percentages of surviving chickens. The log-rank (Mantel-Cox) test was used to compare survival curves. *statistically significant difference (P < 0.05) in comparison to PBS group. ¤statistically significant difference (P < 0.05) between the indicated groups.

Back to article page